ARISTOTLE trial

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
Yahoo/BusinessWire
Sun, 08/28/11 - 12:22 pm
Eliquis
Apixaban
Warfarin
atrial fibrillation
stroke
Bristol-Myers Squibb
Pfizer
ARISTOTLE trial